Health Care • Biotechnology: Biological Products (No Diagnostic Substances)
$191.31 ▲ +1.04
(+0.55%)
MKT CAP: $41.00B • VOL: 1.10M
52W L $58 52W H $224
CONSENSUS RATING DISTRIBUTION (40 DESKS)
BUY: 30 HOLD: 8
SELL: 2
12M STREET TARGET RANGE
IMPLIED: +14.0%
LOW
$161
MEDIAN
$214
MEAN
$218
HIGH
$260
STREET BS CREDIBILITY SCORE 1Y BACKTESTED
68/100
EMPIRICAL HIT RATE VS SPOT
GRADES WHETHER SELL-SIDE TARGET REVISIONS LEAD OR CHASE RVMD TAPE
RVMD // FIRM-BY-FIRM ANALYST BACKTEST & BS DETECTOR (ANR <GO>)
CURRENT 90D STREET CONSENSUS
| INSTITUTION / ANALYST | ACTION | RATING | TARGET | PRIOR PT | CALL DATE | PX AT CALL | RET SINCE CALL | 1Y ACCURACY | BS GRADE |
|---|---|---|---|---|---|---|---|---|---|
| Morgan Stanley Institutional Equity Desk | REITERATE | OUTPERFORM | $231.49 | $220.01 | 2025-02-14 | $174.09 | +9.9% | 78% | A |
| Goldman Sachs Global Research Sector Coverage | TARGET REV | STRONG BUY | $241.05 | $225.75 | 2025-02-06 | $179.83 | +6.4% | 74% | A |
| J.P. Morgan Securities US Large Cap | REITERATE | BUY | $218.09 | $210.44 | 2025-01-29 | $183.66 | +4.2% | 67% | B |
| Bernstein Autonomous Forensic Coverage | INITIATE | HOLD | $195.14 | — | 2025-01-17 | $187.48 | +2.0% | 61% | B |
| Barclays Capital Americas Research | DOWNGRADE | UNDERPERFORM | $168.35 | $181.74 | 2025-01-09 | $170.27 | -11.2% | 42% | D |
| UBS Investment Bank Institutional Desk | UPGRADE | BUY | $227.66 | $198.96 | 2024-12-18 | $166.44 | +14.9% | 72% | A |
| Citigroup Global Markets Sector Lead | TARGET REV | HOLD | $185.57 | $193.22 | 2024-12-04 | $177.92 | -4.3% | 48% | C |